Results 61 to 70 of about 9,237 (252)

Does electromagnetic hypersensitivity originate from nocebo responses?: Indications from a qualitative study [PDF]

, 2015
International audienceIdiopathic Environmental Intolerance attributed to Electromagnetic Fields (IEI-EMF) is a condition in which symptoms are attributed to electromagnetic field (EMF) exposure. As electro-hypersensitive (EHS) people have repeatedly been
Dieudonné, Maël
core   +2 more sources

Questioning the Consensus on Placebo and Nocebo Effects [PDF]

Psychotherapy and Psychosomatics, 2020
Letter to the ...
Hardman, Doug, Hutchinson, Phil, Ongaro, Giulio   +2 more
openaire   +4 more sources

Regulation with Placebo Effects [PDF]

, 2008
A growing scientific literature supports the existence of placebo effects from a wide range of health interventions and for a range of medical conditions.
Malani, Anup
core   +1 more source

The Nocebo Effect in Childbirth Classes [PDF]

The Journal of Perinatal Education, 2013
Patients are well-known to experience a placebo response to medications or treatments. It is less well-known that they can also experience a nocebo response where they have negative effects from something that should be ineffective. In recent literature, the words of medical providers have been demonstrated to create illness responses without physical ...
openaire   +2 more sources

Adherence to guideline‐directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy

European Journal of Heart Failure, EarlyView.
Heart failure (HF) affects over 60 million individuals globally. Contemporary guideline‐directed medical therapies (GDMT) reduce cardiovascular mortality and HF hospitalizations. However, medication non‐adherence represents a critical barrier limiting real‐world efficacy of GDMT.
Gianluigi Savarese, Felix Lindberg, Antonio Cannata, Marianna Adamo, Giuseppe Ambrosio, Pietro Ameri, Markus S. Anker, Magnus Bäck, Antoni Bayes‐Genis, Tuvia Ben Gal, Frieder Braunschweig, Ovidiu Chioncel, Emilia D'Elia, Hassan El‐Tamimi, Gerasimos Filippatos, Nicolas Girerd, Loreena Hill, Ewa Jankowska, Kamlesh Khunti, Basil S. Lewis, Brenda Moura, Offer Amir, Stefania Paolillo, Massimo Piepoli, Abdulla Shehab, Maggie Simpson, Hadi Skouri, Davide Stolfo, Carlo Gabriele Tocchetti, Cristiana Vitale, Maurizio Volterrani, Stephan von Haehling, Sven Wassmann, Mehmet Birhan Yilmaz, Juan Carlos Kaski, Dobromir Dobrev, Marco Metra, Giuseppe M.C. Rosano   +37 more
wiley   +1 more source

Placebo and the law of identification

Frontiers in Psychiatry
Thousands of essays and studies have been published on placebo and nocebo. Yet, despite this plethora of information, we are not much closer to a comprehensive understanding of the fundamental mechanism producing placebo and nocebo effects than we were ...
Steve F. Bierman, Andrew Weil, Stephen Dahmer   +2 more
doaj   +1 more source

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review

Frontiers in Pharmacology, 2019
Background: Nocebo refers to adverse events related to patients’ negative expectations and previous experiences, mediated by several neurobiological pathways within the brain.
Ioanna Spanou, Theodoros Mavridis, Dimos D. Mitsikostas   +2 more
doaj   +1 more source

Underappreciated power. Placebo and nocebo in medicine

Медицинский совет, 2020
The term placebo is defined as a substance with no therapeutic effect that improves health by convincing the patient that the substance is effective. The term comes from the Latin “placere”, meaning “I will delight” or “do good”.
A. O. Bueverov
doaj   +1 more source

Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis

Frontiers in Medicine, 2022
ObjectiveTo estimate the magnitude of the nocebo response and explore its influencing factors in irritable bowel syndrome (IBS).MethodsThe PubMed, Embase, and Cochrane Library databases were searched up to March 2021.
Ruijie Li, Fuping Chen, Xuanxuan He, Yuqing Feng, Qiaoqiao Pei, Dongke Wang, Xinghuang Liu, Jinsong Liu, Xiaohua Hou, Tao Bai   +9 more
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source